

Therapeutic Goods Administration (TGA) Approval of ReadyAttentionGo!

Highlights

- Successful design transfer of pipeline product, ReadyAttentionGo!
- ReadyAttentionGo! obtains Class I Medical Device Certification
- Therapeutic Goods Administration (TGA) clears ReadyAttentionGo! for Australian Market Access

TALi Digital Ltd (ASX:TD1, "TALi" or "the Company"), a leading health technology business pioneering in the cognitive attention function and in-attention space, has today announced the successful certification and approval of its new product, ReadyAttentionGo! as a class I Medical Device (ARTG: 404856).

The TALi team successfully completed design and development of ReadyAttentionGo! in February 2023, as a Software as Medical Device under the company's ISO 13485 IEC62304 and ISO 14971 compliant Quality Management System to ensure safe and effective product design.

ReadyAttentionGo! is intended to be used as a cognitive trainer available on a tablet to develop the cognitive function of attention in children between the ages of 3-10, by playing digitised and gamified tasks under the direction of a healthcare professional. ReadyAttentionGo! is an adjunctive tool and is not intended to be used as a stand-alone diagnostic or screener.

Release authorised by:

The Board of TALi Digital Limited

CONTACT

Corporate

Dr Mary Beth Brinson
Chief Executive Officer
TALi Digital
1300 082 013
investors@talidigital.com

Investors

Mark Simari
Chair
TALi Digital
1300 082 013
investors@talidigital.com

About TALi Digital

TALi Digital Limited (ASX: TD1) is a digital health company delivering diagnostic and therapeutic solutions to enhance attention cognitive function. The Company has built a patented platform technology with our first programs targeting cognitive attention skills during early childhood via an evidence-based screening tool (DETECT®) and training modules (TRAIN® and ReadyAttentionGo!).

These programs are designed to be play-based interactions and can be complementary to existing therapy, placing TALi at the forefront of improving early intervention for childhood attention and concentration performance, which supports our vision to deliver a personalised digital experience to enhance cognitive care.

A continuous innovation focus will see the Company deliver a series of product developments relevant to ADHD (Attention Deficit Hyperactivity Disorder) and ASD (Autism Spectrum Disorder).

Learn more at talidigital.com.